Efficacy and Safety of a Novel Herbal Medicine in the Treatment of Irritable Bowel Syndrome: A Randomized Double-Blinded Clinical Trial

Table 1

Baseline characteristics and IBS-related summary measures of randomized patients.

Baseline information	Intervention group ()	Control group ()	value
Mean age (years),			0.23
Females, (%)	19 (59.37%)	20 (62.5%)	0.47
BMI (kg/m^2),			0.58
IBS disease duration (years), (%)
<1	9 (28.12)	12 (37.5)
1-5	15 (46.87)	13 (40.62)
>5	8 (25)	7 (21.87)
IBS subtype by predominant bowel habit, (%)
IBS-D	10 (31.2)	13 (40.6)
IBS-C	8 (25)	7 (21.8)
IBS-M/U	14 (43.7)	12 (37.5)

IBS: irritable bowel syndrome; IBS-SSS: IBS Symptom Severity Scale; IBS-D: diarrhea-predominant IBS; IBS-C: constipation-predominant IBS; IBS-M/U: IBS with mixed symptoms/unsubtyped IBS; s.d.: standard deviation.